Report overview
The global Ibritumomab Tiuxetan market was valued at million in 2024 and is projected to reach US$ million by 2032, at a CAGR of %during the forecast period.
It is the world"s first radiolabeled monoclonal antibody, launched in the United States in 2002 and approved for the treatment of refractory and relapsed B-cell non-Hodgkin"s lymphoma. Radioimmunization represented by Zevalin marks a new era for human treatment of non-Hodgkin lymphoma. Zevalin combines the excellent targeting of monoclonal antibodies and the powerful radiotherapy effect of radioisotopes, so it can maximize the effect of radiotherapy. kill tumor cells.
The U.S. market is estimated at $ million in 2024, while China is to reach $ million.
0.05 segment will reach $ million by 2032, with a % CAGR in next six years.
The global key players of Ibritumomab Tiuxetan include CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma, Kedrion, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
We have surveyed the Ibritumomab Tiuxetan companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Ibritumomab Tiuxetan, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ibritumomab Tiuxetan. This report contains market size and forecasts of Ibritumomab Tiuxetan in global, including the following market information:
Global Ibritumomab Tiuxetan market revenue, 2020-2025, 2026-2032, ($ millions)
Global top five Ibritumomab Tiuxetan companies in 2024 (%)
Total Market by Segment:
Global Ibritumomab Tiuxetan market, by Type, 2020-2025, 2026-2032 ($ millions)
Global Ibritumomab Tiuxetan market segment percentages, by Type, 2024 (%)
0.05
0.25
Global Ibritumomab Tiuxetan market, by Application, 2020-2025, 2026-2032 ($ millions)
Global Ibritumomab Tiuxetan market segment percentages, by Application, 2024 (%)
Follicular Non-hodgkin Lymphoma
Metastatic B-cell Non-hodgkin Lymphoma
Global Ibritumomab Tiuxetan market, by region and country, 2020-2025, 2026-2032 ($ millions)
Global Ibritumomab Tiuxetan market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ibritumomab Tiuxetan revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Ibritumomab Tiuxetan revenues share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
CASI Pharmaceuticals
Biogen
Bayer
Spectrum
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Outline of Major Chapters:
Chapter 1: Introduces the definition of Ibritumomab Tiuxetan, market overview.
Chapter 2: Global Ibritumomab Tiuxetan market size in revenue.
Chapter 3: Detailed analysis of Ibritumomab Tiuxetan company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ibritumomab Tiuxetan in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
